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Background: Cognitive dysfunction represents a distinct biological and clinical dimension
in major depression disorders (MDD) and cognitive performance strongly affects psychoso-
cial functioning in patients diagnosed with MDD.
Objective: To assess which neurocognitive variables at baseline predict the functional outcome
of MDD patients in a 1-year follow-up study as assessed by Functioning Assessment Short Test
(FAST) and whether the improvement observed on affective and cognitive symptoms in our 12
week-prospective observational study after treatment with selective serotonin reuptake inhibitors
(SSRIs) and selective noradrenalin reuptake inhibitors (SNRIs) can affect the following long-term
psychosocial functional outcome at 1 year in the same MDD patients.
Methods: We recruited a total of 31 patients (8 males; 23 females) with MDD who had
previously completed a pharmacological treatment with SSRIs (n = 22) or SNRIs (n = 9) for
12 weeks, and then continued the same pharmacological treatment for 1 year. After an
average 1-year follow-up, they were interviewed with the FAST to assess functional out-
come. Multivariate analyses were applied to identify clinical and neurocognitive predictors
of functional outcome.
Results: Total Montreal Cognitive Assessment (MoCA), Digit Span forward (Span F) and
backward (Span B), and 15 Rey words immediate recall (Rey I) scores significantly correlated
with FAST. However, after performing regression models only Rey immediate recall score was
useful to predict long-term functional outcome (Pearson correlation coefficient R= −0.68,
p < 0.001) in four specific subdomains of FAST. When considering changes in affective and
cognitive symptoms at the end of the 12 weeks of pharmacological treatment with SSRI or
SNRIs (T1-T0) bymultiple regression analysis, we found that Span F-test predicted scores in the
FAST leisure domain, whereas, changes in Span F, Frontal Assessment Battery (FAB) and Rey
I predicted psychosocial functioning in the specific “cognitive” subdomains of FAST.
Conclusion: Our data suggest that long-term psychosocial functioning can be influenced by
neurocognitive performance at baseline, with verbal memory playing a key role in overall
functioning. Furthermore, improvement in verbal memory can predict functional outcome at
one year in MDD patients with a recent history of partial response to antidepressants.
Keywords: major depression, SSRI, SNRI, cognition, psychometric tools, antidepressant drugs
Introduction
Major Depressive Disorder (MDD) is a severe mental illness that affects 5 to 20%
of the general population.1,2 Epidemiological studies have shown that depression is
estimated to affect 350 million people worldwide. The World Mental Health Survey
conducted in 17 countries found that on average about 1 out of 20 people reported
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having an episode of depression in the previous year
(World Health Organization, 2008).
The last version of the Diagnostic and Statistic Manual
of Mental Disorder (DSM 5)3 describes MDD as
a condition characterized by somatic and cognitive
changes that significantly affect the individual’s capacity
to function.4 Some authors have found a significant asso-
ciation between depression and disability.5,6
Cognitive dysfunction represents a distinct biological
and clinical dimension in MDD. It is well known that
cognitive performance strongly affects psychosocial func-
tioning and, particularly, working ability in patients diag-
nosed with MDD7 as well as with bipolar disorder.8,9
A study conducted by Bonnìn et al10 on bipolar patients
showed that depressive symptoms, combined with neuro-
cognitive damage impairment related to executive func-
tions and working memory, are predictors of long-term
functional abilities. Other studies conducted in patients
with bipolar disorder and aimed to evaluate the predictive
value of cognitive impairment on long-term individual
functioning have shown that both cognitive deficits and
the duration of depressive episodes are associated with an
impairment of functional abilities.11 Evans et al12 system-
atically reviewed the evidence on neurocognitive deficits
and their relationships to psychosocial functioning in
MDD, reporting that test performance in at least one
cognitive domain was associated with a predicted func-
tional outcome in all included studies.
Recently, Jha et al13 found that in depressed patients,
although highly impaired at baseline, non-work-related
activity significantly improves with treatment and also
independently predicts long-term clinical outcomes.
A recent 12 week-prospective observational study in
MDD patients with a recent history of partial response to
antidepressants performed by our group indicated that
Selective Serotonin Reuptake Inhibitors (SSRIs) and
Serotonin and Noradrenaline Reuptake Inhibitors
(SNRIs) can improve cognitive symptoms in MDD inde-
pendently from their efficacy on affective symptoms,14 but
it remains unclear whether or not the clinical improvement
observed after a 12-week treatment can then affect func-
tional abilities in a long-term perspective (1-year). In
addition, cognitive side effects were reported in over
20% of patients suffering from depression or anxiety suc-
cessfully treated with SSRIs over 6 months.15 Therefore,
a long-term evaluation of antidepressants efficacy requires
a long-term assessment of functional abilities.
The aim of the present follow-up study was to assess: i)
which neurocognitive variables at baseline best predict the
functional outcome of MDD patients in a 1-year follow-up
study as assessed by Functioning Assessment Short Test
(FAST); ii) whether the improvement observed on affec-
tive and cognitive symptoms in our 12 week-prospective
observational study after treatment with SSRIs and SNRIs
can affect the following long-term psychosocial functional
outcome at 1 year in the same MDD patients.
Methods
Study Design
The study was approved by the ethical committees ASP3
Catania-Villa dei Gerani Clinic (July 24 2012). The study
met the ethical administrative Italian legislation in force
when the study administrative process started (03.06.2012)
according to CM 6 02.09.2002, GU 214 12.09.2002 and
D 29.03.2008 of the Italian Medicine Agency (Agenzia
Italiana del Farmaco, AIFA) and GU 76 31.03.2008, Art
10 (Procedures for Observational Studies).
The designed study was a prospective, observational
(non-interventional), cohort study. The study complied
with the definition of “observational” (i.e. “non-
interventional”) study provided in Article 2(c) of
Directive 2001/20/EC, meaning that the investigator who
carries out the study does not interfere with the physician’s
decision regarding which drug is clinically pertinent to be
prescribed to each individual patient. Therefore, prescrip-
tion of SSRIs or SNRIs solely resulted from an indepen-
dent clinical evaluation, according to the physician’s
clinical judgment, and based on each patient’s clinical
profile. Moreover, the decision to include a patient in the
study, following his/her agreement, was taken indepen-
dently of the clinical decision to prescribe SSRIs or
SNRIs. Finally, the study did not affect the medical prac-
tice of participating physicians and did not trigger addi-
tional medical visits. In this respect, we carried out a 12
week-prospective observational study examining the effec-
tiveness of SSRIs versus SNRIs in standard medical prac-
tice, in two cohorts of moderate-severe MDD patients,
selected for their recent history of partial response to
antidepressants (in the last 4 weeks). Partial response
was evaluated at the beginning of the 12 week-
prospective observational study and defined as
a reduction in Hamilton Depression Rating Scale for
Depression (HDRS) score ≥25% but <50%.
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Subjects
Patients were recruited at the Psychiatric Clinic “Villa dei
Gerani” (Catania, Italy) and provided written informed
consent. The study was conducted in accordance with the
Declaration of Helsinki.
Thirty-one patients with MDD (8 males; 23 females),
aged between 34 and 72 years, were selected for the
present study from the larger sample of 49 partial respon-
ders MDD who previously completed our 12-week obser-
vational study conducted between 2014 and 2015.14
Patients were recruited with the following inclusion cri-
teria: 1)MDD diagnosis according to DSM criteria (DSM-IV
TR and DSM-5); 2) Age >30 and <75 years; 3) To have
previously completed the observational study14 and the phar-
macological treatment with SSRIs (n= 22) or SNRIs (n=9)
for 12 weeks and, then, continued the same pharmacological
treatment for 1 year (12 weeks of treatment during the
observational study plus 9 months of follow-up).
Exclusion criteria were: 1) history of mental retardation
or any clinical condition that could affect cognitive perfor-
mance; 2) presence of manic or hypomanic episodes; 3)
presence of other psychiatric disorders in comorbidity; 4)
presence of other pharmacological treatments for psychiatric
disorders (antipsychotics, mood stabilizers and benzodiaze-
pines), and 5) presence of substance abuse/dependence.
The 22 MDD patients of the SSRI group completed the
12 weeks treatment (T2) and continued the pharmacologi-
cal treatment up to 1 year with the following drugs: esci-
talopram (10 mg/day, n=11); paroxetine (20 mg/day, n=4),
citalopram (20 mg/day, n=7). The remaining 9 MDD
patients of the SNRI cohort completed the 12 weeks treat-
ment with the following drugs: venlafaxine (225 mg/day,
n=4), duloxetine (60 mg/day, n=5).
Neuropsychological Assessment
During the observational study, patients underwent cognitive
and neuropsychiatric assessments carried at baseline and at
the end of the 12-weeks of pharmacological treatment. At
baseline depressive symptoms were assessed by the
Hamilton Depression Rating Scale (HDRS)16,17 and the
Beck Depression Inventory (BDI–II).18 The patients were
also assessed by a comprehensive neuropsychological bat-
tery consisting of: 1) Tools for the assessment of global
cognitive function: Mini Mental State Examination
(MMSE)19 and Montreal Cognitive Assessment (MoCA),20
and 2) Tools for the assessment of specific cognitive func-
tions: Rey 15 Words Test21 and Verbal memory span (Digit-
Span)22 was used to measure the short-term memory of
participants23 and Frontal Assessment Battery to measure
executive functions (FAB).24
The Functioning Assessment Short Test (FAST)25 was
used as a primary outcome at study endpoint to identify
predictors for specific functioning domains, such as: auton-
omy, occupational functioning, cognitive functioning, finan-
cial issues, interpersonal relationships and leisure time. The
FASTwas assessed after an average period of 1 year-follow-
up after the beginning of the pharmacological treatment. For
this study, we only analyzed the score of the overall func-
tioning and the score of four specific FAST scale domains.
Statistical Analyses
First, we preliminarily tested Spearman correlations to verify
which clinical and neurocognitive variables at baseline were
related to total FAST score at one year of follow-up. Rank
correlation bymeans of Spearman test was selected because of
the impossibility to assure the normality of distribution of all
the variables necessary for using parametric tests. A threshold
of P <0.1 was considered significant for selection of the vari-
able for further investigation through linear regression analysis
with both total FAST score and individual sub domains FAST
scores as dependent variables. Subsequently, changes in affec-
tive and cognitive symptoms detected in MDD patients at the
end of the observational study (12 weeks) were tested, after
Bonferroni correction, through linear regression analyses
adjusted for potential confounding factors [such as baseline
clinical (e.g., depression severity, dosage) and demographic
(e.g., age, gender) variables] to verify whether the clinical
improvement observed at the end of the 12 weeks of pharma-
cological treatment affected psychosocial performance evalu-
ated by FAST total score at one year of follow-up. All analyses
were performed by software SYSTAT 12.0.
Results
Correlation Between Baseline Affective
and Cognitive Symptoms and
Psychosocial Functioning
The main sociodemographic and clinical characteristics of
MDD patients are presented in Table 1.
We first analyzed the correlation between cognitive and
affective symptoms at baseline and FAST total score one year
after the beginning of the pharmacological treatment in the 22
MDD patients treated with SSRIs and in the 9 MDD patients
treated with SNRIs. In particular, we considered MMSE,
MoCA scores for global cognitive function, FAB scores for
Dovepress Castellano et al
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executive function, Span forward, Rey’s 15 Words Test and
delayed Rey test scores for verbal memory, Span backward
scores for working memory, whereas HDRS and BDI–II were
used for baseline affective symptoms. The FAST total score
was negatively significantly correlated with FAB, MoCA,
SPAN at baseline in the unadjusted model, but only theMoCA
(rs= −0.48; p=0.06), SPAN forward (rs= −0.46; p=0.08), and
Rey immediate recall scores (rs= −0.66; p<0.001) were con-
sidered for further analyses. No other correlations were found
between FAST total score and baseline MMSE, Span
Backward, delayed Rey test scores for verbal memory and
psychosocial functioning at 1 year follow up.
When considering baseline affective symptoms, no corre-
lation was found with FAST total scores. In particular, a trend
of positive correlation was detected with BDI baseline scores,
whereas a negative correlation was found between baseline
HDRS scores and FAST total scores at 1 year (Table 2).
Interestingly, we found a high positive correlation between
the BDI baseline score and the FAST cognitive functioning
domain at 1 year of follow-up (r=0.33; p<0.05). Besides,
a significant negative correlation was found between the
HDRS baseline test score and the financial capacities
(r=0.36; p<0.05). An inverse, although not significant, correla-
tion was observed between total FAST and HDRS scores.
Regression Models
On the basis of the preliminary correlation analysis, using the
variables significantly correlated with FAST (i.e. total MoCA,
SPAN forward, and Rey immediate recall scores), we then
performed regression models to assess which cognitive vari-
ables at baseline better predict functional outcome at one year
follow-up. Only Rey immediate recall score was useful to
predict long-term functional outcome (beta = −0.68, p<0.001).
More in detail, Rey immediate recall score predicts psychoso-
cial functioning in 4 specific subdomains of FAST, i.e. the
autonomy domain, the FAST financial domain, the FAST inter-
personal domain and the leisure domain (Table 3, Figure 1).
Subsequently, we examined whether changes in affective
and cognitive symptoms at the end of the 12 weeks of phar-
macological treatment with SSRI or SNRIs (T1-T0) were
associated with overall psychosocial functioning at 1 year of
follow up as assessed by the total FAST score. We found that
the change detected in the Span forward test correlated with
FAST total score (rs= 0.47) and the differences detected
between T1 and T0 with the Rey immediate recall t-test (rs=
0.47), although after Bonferroni correction both were not
significant. We then performed linear regression analyses to
establish which of the three cognitive tests (Span F, FAB,
ReyI) better predicted FAST total score. We found that only
changes in scores from Span forward test were able to predict
psychosocial functioning (Table 4). In particular, changes in
scores from Span forward test after 12 weeks predicted scores
in the FAST leisure domain, whereas changes in all of the three
cognitive tests (Span F, FAB, Rey I) predicted psychosocial
functioning in the specific “cognitive” subdomains of FAST.
Finally, we detected, despite not significant, a trend of
correlation (Rs 0.33; p=0.07) between changes in HDRS
scores at 12 weeks of treatment and total FAST scores,
whereas no correlation was found between changes in BDI
scores and psychosocial functioning.
Discussion
Results of the present study indicate that neurocognitive
performance at baseline, particularly verbal memory,
affects long-term psychosocial functioning.
Besides, in MDD patients with a recent history of
partial response to antidepressants, functional outcome at
one year can be predicted by the improvement in verbal
memory.
Table 1 Sociodemographic and Clinical Characteristics of MDD
Patients
Patients (n = 31)
Age; mean (SD) 54.71 (12.04)
MMSE baseline, mean (SD) 25.31 (4.30)
HDRS baseline mean (SD) 22.55 (7.38)
BDI baseline, mean (SD) 33.29 (11.91)




Antidepressant therapy, n (%)
SSRI 22 (71)
SNRI 9 (29)
Table 2 Correlations Between Baseline Cognitive Variables and
Total FAST Score
FAST p p*
MMSE_T0 −0.42 0.02 0.18
MOCA_T0 −0.48 0.01 0.06
FAB_T0 −0.39 0.03 0.26
SPAN_F_T0 −0.46 0.01 0.08
SPAN_B_T0 −0.43 0.02 0.14
REY_I_T0 −0.66 0.00 0.00
REY_D_C_T0 −0.23 0.22 1.00
Notes: *After Bonferroni correction. Bold values indicate statistical significance.
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Cognitive deficits are considered as key symptoms of
clinical depression associated with reduced psychosocial
functioning in MDD patients26 and in particular with def-
icits in working ability.7 Two important open questions
still remain: a) whether cognitive factors at baseline
(before initiating a pharmacological treatment) can predict
the functional outcome of MDD patients in 1-year follow-
up study, and b) whether clinical improvement in cognitive
symptoms after an adequate treatment with second-
generation antidepressants drugs can influence long-term
psychosocial functioning in MDD patients.
In the present study, we found that only specific cognitive
factors, such as free delayed recall (verbal memory), are sig-
nificant predictors of long-term functional outcome in MDD
patients as assessed at 1 year of follow up with a specific
functioning scale (FAST). FAST is a psychometric tool devel-
oped to assess psychosocial functioning in patients with bipo-
lar disorder and validated in clinical samples.27,28 It is known
that cognitive reserve is correlated with psychosocial function-
ing and, thus, with FAST score in bipolar patients.10 Other
studies demonstrated a cross-sectional link between verbal
memory and poor overall functioning in bipolar patients.29–31
The present study is the first long-term study demonstrat-
ing the predictive value of neurocognitive performance (Rey
immediate recall score) on long-term functional outcome in
unipolar-depressed patients. In particular, Rey immediate
recall score predicted psychosocial functioning in different
specific subdomains of FAST such as autonomy, financial,
interpersonal domain and leisure domains (Table 3).
Although a trend of correlation was found with MoCA and
SPAN forward scores, statistical significance was not
reached probably due to the small sample size.
Cognitive domains have been shown to have consider-
able impact on vocational functioning including deficits in
memory, attention, learning and executive function.32
However, in the present study executive dysfunction did
Table 3 Multiple Regression Analysis Between Cognitive Tests and FAST at 1 Year of Follow-Up
Autonomy Financial Interpersonal Leisure
R2 0.47 R2 0.41 R2 0.27 R2 0.29
Std. Coeff. p-value Std. Coeff. p-value Std. Coeff. p-value Std. Coeff. p-value
MOCA −.12 .65 .36 .19 .18 .55 .50 .10
SPAN_F −.26 .23 −.41 .07 −.02 .93 −.21 .37














Figure 1 Plot of the relationship between Rey immediate recall scores (Rey-I) and FAST.
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not predict psychosocial functioning. Recent studies
demonstrated that deficits in executive functioning in
MDD are associated with psychosocial outcomes as
assessed by FAST.33 Future studies with larger sample
size and longer follow-up are needed to better understand
the predictive value of this cognitive factor in MDD.
Interestingly, no correlation was found between psycho-
metric tests assessing affective symptoms at baseline (HDRS,
BDI) and functional outcome at one year. Furthermore, the
scores from BDI showed a trend of positive correlation with
FAST total scores as opposite to HDRS scores, suggesting that
the adopted instrument (self-report versus rating scale) can
strongly affect data analysis and results. These results also
suggest that the severity of cognitive symptoms probably
exerts a more relevant role compared to affective symptoms
in determining long-term functional abilities.
Another finding of our study is that changes in cognitive
symptoms (i.e. verbal memory) continue to affect psychoso-
cial functioning after one year of treatment. Interestingly,
changes in three different cognitive tests (Span F, FAB, Rey
I) were able to predict psychosocial functioning in the spe-
cific “cognitive” subdomains of FAST, suggesting that this
tool is able to detect deficits in functional abilities strictly
related to specific cognitive deficits in MDD.
The present study has some limitations intrinsically to
the observational design (i.e. absence of randomization
and of control group, no treatment-intervention, groups
not matched for number, sex and treatment) and the dura-
tion of the study. Other limitations are small sample size
and the heterogeneity of the pharmacological treatments
(two pharmacological classes of antidepressants and four
different molecules not equally distributed in the sample).
Moreover, the study did not include during the observa-
tional period any treatment with vortioxetine, which is one
of the few antidepressants with positive primary effects on
cognitive performance,34 because the drug was not mar-
keted at that time. Thus, further studies are needed in order
to validate these findings.
Taken together, our data suggest that long-term psy-
chosocial functioning can be influenced by neurocognitive
performance at baseline, with verbal memory playing
a key role in overall functioning. Thus, clinicians, preli-
minarily to pharmacological treatment, should consider to
assess cognitive functions at base. Furthermore, improve-
ment in verbal memory can predict functional outcome at
one year in MDD patients with a recent history of partial
response to antidepressants.
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